Nashville-Davidson, Tennessee 2021-10-04 08:43:17 –
(NEXSTAR) — Johnson & Johnson will seek federal regulator approval for the COVID-19 booster shot earlier this week. New York Times Reported on Monday. The news comes from officials familiar with the company’s plans.
Last month, regulators approved booster shots for some recipients of the Pfizer-BioNTech vaccine, and this month they are considering approval for recipients of the Moderna vaccine.
Federal officials are concerned that more than 15 million US recipients of the J & J vaccine are at too high a risk of serious COVID-19, the Times reported.
The Food and Drug Administration on Friday scheduled a meeting of its advisory board on October 15 to discuss whether to grant an emergency use authorization for J & J Booster Shot.
According to the US Centers for Disease Control and Prevention You are fully vaccinated after 2 weeks Receive a second vaccination with Pfizer or Moderna vaccine, or a single J & J vaccination.
Vaccines provide strong protection against serious illness, but U.S. health officials now rely on COVID-19 based on evidence that protection against mild illness may be diminished, especially among the elderly. We recommend booster immunization for some people at high risk of serious illness.
According to the CDC, caregivers over the age of 65 and people between the ages of 50 and 64 with health problems such as diabetes and heart disease will get a booster if they get a Pfizer shot at least 6 months ago. need to do it.
The agency has stopped recommending boosters to people between the ages of 18 and 49 who have health problems, but says they can still be shot after considering individual risks. The same is true for people between the ages of 18 and 64, who may be at increased risk of infection due to work, such as health workers, teachers, first responders, agricultural workers, and public transport workers.
last month, Johnson and Johnson announced The second dose of the vaccine, if given two months after the first dose, increases efficacy by about 22 percentage points to 94%.
“Our single-shot vaccine produces a strong immune response and long-term immunological memory, and given the boost immunity of Johnson & Johnson’s COVID-19 vaccine, it provides a strong defense against COVID-19. It will be even higher, “said Johnson & Johnson’s Global Head of Research and Development Janssen, Dr. Matai Mamen, in a statement at the time.
The Associated Press contributed to this report.
Johnson & Johnson set to seek authorization for its booster shot Source link Johnson & Johnson set to seek authorization for its booster shot